Why European and United States drug regulators are not speaking with one voice on anti-influenza drugs: regulatory review methodologies and the importance of ‘deep’ product reviews

BACKGROUND: Relenza represents the first neuraminidase inhibitor (NI), a class of drugs that also includes the drug Tamiflu. Although heralded as breakthrough treatments in influenza, NI efficacy has remained highly controversial. A key unsettled question is why the United States Food and Drug Admin...

Descripción completa

Detalles Bibliográficos
Autores principales: Mulinari, Shai, Davis, Courtney
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5680823/
https://www.ncbi.nlm.nih.gov/pubmed/29121959
http://dx.doi.org/10.1186/s12961-017-0259-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5680823/
https://www.ncbi.nlm.nih.gov/pubmed/29121959
http://dx.doi.org/10.1186/s12961-017-0259-8

Ejemplares similares